View of statins as antimicrobials in cardiovascular risk modification

被引:22
|
作者
Kozarov, Emil [1 ,2 ]
Padro, Teresa [1 ]
Badimon, Lina [1 ,3 ]
机构
[1] Biomed Res Inst St Pau IIB St Pau, Cardiovasc Res Ctr CSIC ICCC, Barcelona 08025, Spain
[2] Columbia Univ, Med Ctr, New York, NY 10032 USA
[3] UAB, Cardiovasc Res Chair, Barcelona, Spain
关键词
Atherosclerosis; Statins; Microbial infection; Inflammation; CHLAMYDIA-PNEUMONIAE INFECTION; ARTERIAL OCCLUSIVE DISEASE; CORONARY-HEART-DISEASE; ACUTE-MYOCARDIAL-INFARCTION; ABDOMINAL AORTIC-ANEURYSMS; SECONDARY PREVENTION TRIAL; RANDOMIZED CLINICAL-TRIAL; A REDUCTASE-ACTIVITY; C-REACTIVE PROTEIN; DOUBLE-BLIND;
D O I
10.1093/cvr/cvu058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is a complex arterial pathological development underlying heart attack and stroke and a leading cause of death in developed and now also in developing countries. The primary processes that lead to the inflammatory lipid-laden proliferative lesion, obstructing the blood flow, and referred to as atherosclerotic plaque are dyslipidaemia and inflammation. Here, we will review one of the most efficient classes of drugs indicated for management of cardiovascular disease (CVD), statins. We will assess their pleiotropic effects that emerged from CVD applications, focusing this review specifically on plausible antimicrobial activity. Only recently gaining strength, the recognition of possible antibacterial activity may extend the statin applicability for vascular as well as to other critical inflammatory conditions.
引用
收藏
页码:362 / 374
页数:13
相关论文
共 50 条
  • [21] Rheumatoid arthritis and cardiovascular risk: perspectives of treatment with statins
    Anichkov, D. A.
    Shostak, N. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2005, 1 (03) : 47 - 53
  • [22] Cardiovascular risk predicted by adherence to statins in a Medicaid population
    Shaya, FT
    Samant, ND
    El Khoury, AC
    VALUE IN HEALTH, 2006, 9 (03) : A121 - A121
  • [23] Does the addition of ezetimibe to statins reduce cardiovascular risk?
    Araya, Francisca I.
    Grassi, Bruno
    MEDWAVE, 2016, 16
  • [24] Reducing cardiovascular risk in postmenopausal women: Estrogen or statins?
    Cannon, RO
    WOMEN'S HEALTH AND MENOPAUSE: NEW STRATEGIES - IMPROVED QUALITY OF LIFE, 2002, 17 : 123 - 130
  • [25] Beyond Statins: Lipid Management to Reduce Cardiovascular Risk
    Schuck, Robert N.
    Mendys, Philip M.
    Simpson, Ross J., Jr.
    PHARMACOTHERAPY, 2013, 33 (07): : 754 - 764
  • [26] Combination therapy of statins and fibrates in the management of cardiovascular risk
    Fievet, Catherine
    Staels, Bart
    CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (06) : 505 - 511
  • [27] Review: Statins reduce mortality and cardiovascular events in adults at risk for cardiovascular disease
    Brugts, J. J.
    Yetgin, T.
    Hoeks, S. E.
    Davidson, Richard A.
    Rosenberg, Eric
    ANNALS OF INTERNAL MEDICINE, 2009, 151 (08)
  • [28] CARDIOVASCULAR RISK MODIFICATION IN CHILDHOOD - HYPERLIPIDEMIA
    WEIDMAN, WH
    MAYO CLINIC PROCEEDINGS, 1986, 61 (11) : 910 - 913
  • [29] MODIFICATION OF CARDIOVASCULAR RISK-FACTORS
    COLQUHOUN, D
    MEDICAL JOURNAL OF AUSTRALIA, 1988, 148 (10) : 538 - 538
  • [30] Nutritional modification of cardiovascular disease risk
    Osler, M
    MIDLIFE HEALTH - CURRENT CONCEPTS AND CHALLENGES FOR THE FUTURE, 2002, 1229 : 109 - 114